ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease
Provided By GlobeNewswire
Last update: Jan 6, 2025
Totality of data observed with subcutaneous lonigutamab in Thyroid Eye Disease (TED) patients demonstrate potential for efficacy in line with standard of care and a more favorable safety profile
Read more at globenewswire.com2.6
+0.43 (+19.82%)
Find more stocks in the Stock Screener
SLRN Latest News and Analysis
2 days ago - ChartmillThese stocks are moving in today's pre-market sessionLet's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session.
2 days ago - ChartmillWondering what's happening in today's after-hours session?The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today.
